CANCER CELL BIOLOGY PROGRAM The overarching goals of the Cancer Cell Biology (CCB) Program are: (i) to understand, at the molecular and cellular levels, mechanisms underlying tumor initiation, progression, metastasis and resistance to therapeutic treatment, and (ii) to identify and validate new targets for cancer therapy. Insight derived from these studies, when integrated with research and development from other programs, will provide targets and guidance for the development of strategies for therapeutic intervention of cancer. Toward these two goals, the Program faculty investigate various aspects of cancer cell biology, including growth factors and receptors; angiogenesis and vascular biology; apoptosis; cell cycle regulation; chromatin biochemistry and transcriptional regulation; cell microstructure and function; DNA replication and repair; metabolism; regulatory RNA; and signal transduction. Led by two co-leaders with complementary expertise, Yue Xiong and James Bear, the program organizes these different areas into four major research aims: (1) Cell Cycle, (2) Cell Signaling, (3) Cell Movement and Organization, and (4) Chromatin Biology. The major emphasis of the Program is to foster integrated research that spans these inter-related themes, enhancing the research and translational capabilities of program investigators through the establishment, expansion and utilization of appropriate core facilities, and promoting interactions with investigators from other LCCC basic, clinical and population sciences programs. CCB has made concerted and focused efforts to improve translational output, by fostering inter-programmatic collaboration directed towards translation of basic science discoveries, engaging in entrepreneurship and brining small molecule inhibitors to pre-clinical and clinical trials. The research of CCB addresses fundamental biology that applies to all cancers but has a particular impact on cancers relevant to our catchment area such as multiple myeloma, lung cancer and melanoma. In addition, members of CCB have been active in community outreach and engagement activities such as advising state legislators on e-cigarette regulation. Finally, the members of CCB are fully committed to education, training and mentoring at levels ranging from middle schoolers through junior faculty at our own institution. The Cancer Cell Biology Program consists of 43 members who are associated with 12 basic science and 3 clinical departments at UNC-Chapel Hill and affiliated institutions. During the last funding period, program members published 740 cancer-related articles. Of these, 23% were inter-programmatic and 10% were intra- programmatic (31% collaborative). In 2019, our program members held grants totaling $18.2M (direct cost) in cancer-relevant extramural funding, including $3.5M (direct costs) from the NCI and $13.6M other peer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016086-45
Application #
10089811
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-06-01
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Song, Wantong; Shen, Limei; Wang, Ying et al. (2018) Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap. Nat Commun 9:2237
Kaur, Gurpreet; Guruprasad, Kunchur; Temple, Brenda R S et al. (2018) Structural complexity and functional diversity of plant NADPH oxidases. Amino Acids 50:79-94
McNeill, Robert S; Stroobant, Emily E; Smithberger, Erin et al. (2018) PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition. PLoS One 13:e0200014
Graham-Gurysh, Elizabeth; Moore, Kathryn M; Satterlee, Andrew B et al. (2018) Sustained Delivery of Doxorubicin via Acetalated Dextran Scaffold Prevents Glioblastoma Recurrence after Surgical Resection. Mol Pharm 15:1309-1318
Trout, Susan; Goldstein, Adam O; Marks, Lawrence et al. (2018) Treating Tobacco Use in Patients with Incurable Malignancies: Should We Even Start the Conversation? J Palliat Med 21:746-750
Lee, Clara Nan-Hi; Pignone, Michael Patrick; Deal, Allison M et al. (2018) Accuracy of Predictions of Patients With Breast Cancer of Future Well-being After Immediate Breast Reconstruction. JAMA Surg 153:e176112
Ricketts, Christopher J; De Cubas, Aguirre A; Fan, Huihui et al. (2018) The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Rep 23:313-326.e5
Golden, Shelley D; Kong, Amanda Y; Lee, Joseph G L et al. (2018) Disparities in cigarette tax exposure by race, ethnicity, poverty status and sexual orientation, 2006-2014, USA. Prev Med 108:137-144
Morgan, Jennifer C; Southwell, Brian G; Noar, Seth M et al. (2018) Frequency and Content of Conversations About Pictorial Warnings on Cigarette Packs. Nicotine Tob Res 20:882-887
Liu, Qi; Zhu, Hongda; Liu, Yun et al. (2018) BRAF peptide vaccine facilitates therapy of murine BRAF-mutant melanoma. Cancer Immunol Immunother 67:299-310

Showing the most recent 10 out of 1525 publications